The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients
Recurrent disease and treatment-associated chemoresistance are the two main factors accounting for poor clinical outcomes of ovarian cancer (OC) patients. Both can be associated with cancer stem cells (CSCs), which contribute to cancer formation, progression, chemoresistance, and recurrence. Hence,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/3/2400 |
| _version_ | 1797624436399013888 |
|---|---|
| author | Natalia Izycka Marcin Rucinski Malgorzata Andrzejewska Sebastian Szubert Ewa Nowak-Markwitz Karolina Sterzynska |
| author_facet | Natalia Izycka Marcin Rucinski Malgorzata Andrzejewska Sebastian Szubert Ewa Nowak-Markwitz Karolina Sterzynska |
| author_sort | Natalia Izycka |
| collection | DOAJ |
| description | Recurrent disease and treatment-associated chemoresistance are the two main factors accounting for poor clinical outcomes of ovarian cancer (OC) patients. Both can be associated with cancer stem cells (CSCs), which contribute to cancer formation, progression, chemoresistance, and recurrence. Hence, this study investigated whether the expression of known CSC-associated markers ALDH1A, CD44, and CD133 may predict OC patient prognosis. We analyzed their expression in primary epithelial ovarian cancer (EOC) patients using immunohistochemistry and related them to clinicopathological data, including overall survival (OS) and progression-free survival (PFS). Expression of ALDH1A1 was detected in 32%, CD133 in 28%, and CD44 in 33% of cases. While Kaplan–Meier analysis revealed no association of the expression of CD133 and CD44 with PFS and OS, ALDH1A1-positive patients were characterized with both significantly shorter OS (<i>p</i> = 0.00022) and PFS (<i>p</i> = 0.027). Multivariate analysis demonstrated that the expression of ALDH1A1, FIGO stage III–IV, and residual disease after suboptimal debulking or neoadjuvant chemotherapy correlated with shorter OS. The results of this study identify ALDH1A1 as a potential independent prognostic factor of shorter OS and PFS in EOC patients. Therefore, targeting ALDH1A1-positive cancer cells may be a promising therapeutic strategy to influence the disease course and treatment response. |
| first_indexed | 2024-03-11T09:42:20Z |
| format | Article |
| id | doaj.art-e3eed4af50a744c7bb13f9bac9e2fe88 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T09:42:20Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-e3eed4af50a744c7bb13f9bac9e2fe882023-11-16T16:56:43ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-01-01243240010.3390/ijms24032400The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer PatientsNatalia Izycka0Marcin Rucinski1Malgorzata Andrzejewska2Sebastian Szubert3Ewa Nowak-Markwitz4Karolina Sterzynska5Department of Gynecology, Obstetrics and Gynecologic Oncology, Division of Gynecologic Oncology, Poznan University of Medical Sciences, Polna 33 St., 60-535 Poznań, PolandDepartment of Histology and Embryology, Poznan University of Medical Sciences, Święcickiego 6 St., 61-781 Poznań, PolandDepartment of Histology and Embryology, Poznan University of Medical Sciences, Święcickiego 6 St., 61-781 Poznań, PolandDepartment of Gynecology, Obstetrics and Gynecologic Oncology, Division of Gynecologic Oncology, Poznan University of Medical Sciences, Polna 33 St., 60-535 Poznań, PolandDepartment of Gynecology, Obstetrics and Gynecologic Oncology, Division of Gynecologic Oncology, Poznan University of Medical Sciences, Polna 33 St., 60-535 Poznań, PolandDepartment of Histology and Embryology, Poznan University of Medical Sciences, Święcickiego 6 St., 61-781 Poznań, PolandRecurrent disease and treatment-associated chemoresistance are the two main factors accounting for poor clinical outcomes of ovarian cancer (OC) patients. Both can be associated with cancer stem cells (CSCs), which contribute to cancer formation, progression, chemoresistance, and recurrence. Hence, this study investigated whether the expression of known CSC-associated markers ALDH1A, CD44, and CD133 may predict OC patient prognosis. We analyzed their expression in primary epithelial ovarian cancer (EOC) patients using immunohistochemistry and related them to clinicopathological data, including overall survival (OS) and progression-free survival (PFS). Expression of ALDH1A1 was detected in 32%, CD133 in 28%, and CD44 in 33% of cases. While Kaplan–Meier analysis revealed no association of the expression of CD133 and CD44 with PFS and OS, ALDH1A1-positive patients were characterized with both significantly shorter OS (<i>p</i> = 0.00022) and PFS (<i>p</i> = 0.027). Multivariate analysis demonstrated that the expression of ALDH1A1, FIGO stage III–IV, and residual disease after suboptimal debulking or neoadjuvant chemotherapy correlated with shorter OS. The results of this study identify ALDH1A1 as a potential independent prognostic factor of shorter OS and PFS in EOC patients. Therefore, targeting ALDH1A1-positive cancer cells may be a promising therapeutic strategy to influence the disease course and treatment response.https://www.mdpi.com/1422-0067/24/3/2400epithelial ovarian cancercancer stem cellsprognosis biomarkerALH1A1CD133CD44 |
| spellingShingle | Natalia Izycka Marcin Rucinski Malgorzata Andrzejewska Sebastian Szubert Ewa Nowak-Markwitz Karolina Sterzynska The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients International Journal of Molecular Sciences epithelial ovarian cancer cancer stem cells prognosis biomarker ALH1A1 CD133 CD44 |
| title | The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients |
| title_full | The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients |
| title_fullStr | The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients |
| title_full_unstemmed | The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients |
| title_short | The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients |
| title_sort | prognostic value of cancer stem cell markers cscs expression aldh1a1 cd133 cd44 for survival and long term follow up of ovarian cancer patients |
| topic | epithelial ovarian cancer cancer stem cells prognosis biomarker ALH1A1 CD133 CD44 |
| url | https://www.mdpi.com/1422-0067/24/3/2400 |
| work_keys_str_mv | AT nataliaizycka theprognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT marcinrucinski theprognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT malgorzataandrzejewska theprognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT sebastianszubert theprognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT ewanowakmarkwitz theprognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT karolinasterzynska theprognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT nataliaizycka prognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT marcinrucinski prognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT malgorzataandrzejewska prognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT sebastianszubert prognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT ewanowakmarkwitz prognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients AT karolinasterzynska prognosticvalueofcancerstemcellmarkerscscsexpressionaldh1a1cd133cd44forsurvivalandlongtermfollowupofovariancancerpatients |